Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06648759 · ClinicalTrials.gov registry record · NA
Vagal Stimulator to Reduce Nasogastric Tube Use
A NA study of Nasogastric Tube Intubation, sponsored by Jacques E. Chelly.
- Recruiting
- Registry status
- NA
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT06648759: Recruiting NA study of Nasogastric Tube Intubation, sponsored by Jacques E. Chelly.
NCT06648759 is a NA study of Nasogastric Tube Intubation that is actively recruiting participants, run by Jacques E. Chelly. The registered enrollment target is 60 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06648759, a NA study of Nasogastric Tube Intubation, is actively recruiting participants, sponsored by Jacques E. Chelly.
- RECRUITING
- Registry status
- NA
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
Abdominal surgery, laparoscopic or open, is frequently performed at UPMC Shadyside hospital. One of the most frequent complications following abdominal surgery is a postoperative ileus. Although postoperative ileus may be the result of obstruction or leakage, in most cases postoperative ileus (POI) is the result of local irritation because of fluid overload, exogenous opioids, neurohormonal dysfunction, gastrointestinal stretch, local bleeding and inflammation. POI usually lasts between 2 to 7 days. In most cases, a nasogastric tube (NG tube) is used to relieve that gastric pressure until the resolution of the POI. The placement of a NG tube can lead to a local trauma, bleeding and pain. Pain represents a major complaint among those with POI, often contributing to prolonged hospital stays.
Primary Outcome
The duration of use of nasogastric (NG) tube will be reported as total of minutes the NG tube is placed and reported in each group as mean(SD) in minutes.
Conditions Studied
Interventions
- DEVICE Vagal Nerve Stimulator
- DEVICE Placebo Vagal Nerve Stimulator
Study Locations (1)
Pennsylvania
- UPMC Shadyside Hospital - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2024-12-04 |
| Est. Completion | 2026-09-30 |
| Phase | NA |
What NCT06648759 shows while recruiting
NCT06648759 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Nasogastric Tube Intubation appearing as the primary indexed condition, and to 2 interventions - of which Vagal Nerve Stimulator is the first listed.
NCT06648759 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT06648759 about?
NCT06648759 is a clinical study titled "Vagal Stimulator to Reduce Nasogastric Tube Use". Abdominal surgery, laparoscopic or open, is frequently performed at UPMC Shadyside hospital. One of the most frequent complications following abdominal surgery is a postoperative ileus. Although postoperative ileus may be the result of obstruction or leakage, in most cases postoperative ileus (POI) ...
What is the current status of trial NCT06648759?
This trial is currently recruiting. It is a NA study. The enrollment target is 60 participants. The study started on 2024-12-04. Estimated completion is 2026-09-30.
What conditions does trial NCT06648759 study?
This clinical trial studies the following conditions: Nasogastric Tube Intubation.
What interventions are being tested in trial NCT06648759?
The interventions under investigation include: Vagal Nerve Stimulator (DEVICE), Placebo Vagal Nerve Stimulator (DEVICE).
Who is sponsoring clinical trial NCT06648759?
This trial is sponsored by Jacques E. Chelly, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06648759 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Nasogastric Tube Intubation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06648759's enrollment target sits among peer trials
60 1164th of 2000 higher than 745 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI